Available online on 15.12.2024 at http://ajprd.com

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

Open Access

Review Article

A Review on Introduction, Importance and Applications of Peptidomimetics.

Patil Kunal*, Chaudhari Anwar[1], Dule Priya, Garkar Rushikesh, Sayais Prashant, Patil Rutik, Jagtap Vaibhav kumar

NES's Gangamai College of Pharmacy, Nagaon, Dhule, (M.S.)

A B S T R A C T

Peptidomimetics, a class of compounds that bridge the gap between peptides and small molecules, have emerged as a transformative class of compounds in drug discovery and therapeutics. Using information from recent studies, this review examines the importance, design approaches, uses, and potential future directions of Peptidomimetic When compared to natural peptides, peptidomimetics show superior stability, selectivity, and versatility. This increases the drug gable space and makes it possible to develop novel therapeutic modalities. Optimizing the pharmacokinetic properties and target interactions of peptidomimetics requires the application of rational design strategies, structural modifications, and synthetic methodologies. Targeting protein-protein inter actions, inhibiting enzymes, and modifying immune checkpoints are examples of diverse therapeutic applications with potential in oncology, infectious diseases, neurology, and other fields. It is the goal of future research directions to embrace interdisciplinary approaches, investigate cutting-edge fields like immunotherapy and precision medicine, and address issues like off-target effects and synthetic accessibility. Peptidomimetics has the potential to significantly transform drug discovery and advance precision medicine techniques for better patient outcomes.

Keyword: Peptidomimetics, Rational Drugs, Drug resistance, Analgesic, Antiviral.

A R T I C L E I N F O: Received 19 Sept. 2024; Review Complete 28 Oct. 2024; Accepted 27 Nov. 2024. ; Available online 15 Dec. 2024

Cite this article as:
Patil K, Chaudhari A, Dule P, Garkar R, Sayais P, Patil R, Jagtap VK, A Review on Introduction, Importance and Applications of Peptidomimetics, Asian Journal of Pharmaceutical Research and Development. 2024; 12(6):86-92,

DOI: http://dx.doi.org/10.22270/ajprd.v12i6.1481

*Address for Correspondence:
Patil Kunal, NES's Gangamai College of Pharmacy, Nagaon, Dhule, (M.S.)

INTRODUCTION

Peptidomimetics Use of peptidomimetics is one of the most recent styles of medicine design and development in medicinal chemistry. These are small protein- suchlike chains which are designed to mimic a peptide [1]. The rubric "peptidomimetics" covers a large and expanding field of exploration that has achieved profound successes and offers fascinating new challenges [2]. Biologically acquainted druggists have been interested in peptidomimetic motes for over a quarter century[3]. In an extensively cited 1993 review [4]. Giannis and Kolter offered a purely functional description "a peptidomimetic is an emulsion that, as the ligand of a receptor, can imitate or block the natural effect of a peptide at the receptor position [5]. Wiley and Rich gave an affiliated description in the same time, "chemical structures designed to convert the information contained in peptides into small no peptide structures [6]. In 1994, Gante Bracket The colorful types of peptidomimetics have been classified as Type- I peptidomimetics or pseudo peptides, Type- II peptidomimetics or functional mimetics, Type- III peptidomimetics or topographical- IV peptidomimetics or on-peptide mimetics Peptides, with their different natural functions and structural versatility, have long been recognized as promising contenders for drug discovery and remedial development [7]. From hormone regulation to cell signaling, peptides play critical places in numerous physiological processes, making them attractive targets for pharmacological intervention. Still, despite their implicit remedial benefits, the clinical paraphrase of peptide-predicated drugshas constantly been hindered by essential limitations analogous as poor stability, limited bioavailability, and vulnerability to enzymatic declination. These challenges

have fueled the explorationof necessary approaches to harness the remedial eventuality of peptides while prostrating their downsides. In response to the limitations associated with natural peptides, the field of peptidomimetics has surfaced as a dynamic and innovative approach in drug discovery and cures of Peptidomimetics are synthetic mixes designed to mimic the structural and functional features of peptides while offering bettered pharmacokinetic parcels, enhanced stability, and increased target particularityincorporating on- peptide rudiments and conformational constraints, peptidomimetics strive to replicate the natural exertion of peptides while addressing the challenges associated with their use as remedial agents[8]. The significance of peptidomimetics lies in their capability to ground the gap between peptides and small molecules, thereby expanding the drug gable space and enabling the development of new curesfor previously challenging targets. Unlike traditional small molecules, which constantly struggle to modulate protein- protein relations or target large, flat protein shells, peptidomimetics offer a unique advantage by furnishing a balcony that can mimic the shape and functional groups of peptides, allowing for precise molecular recognition and commerce with target proteins. This capability to mimic the three- dimensional structure of peptides while retaining the synthetic vacuity and pharmacokinetic parcels of small molecules makes peptidomimetics precious tools in drug discovery and development. In this period of perfection medicine, where the emphasis is on accommodating antidotes to individual cases predicated on their heritable makeup, peptidomimetics offer unknown openings for the design and optimization of targeted cures. By employing the power of rational design strategies, structural variations, and innovative synthetic methodologies, researchers can OK- tune the parcels of peptidomimetics to optimize their effectiveness, selectivity, and safety lives for specific remedial operations? Whether targeting protein-protein relations, enzyme inhibition, or other molecular processes, peptidomimetics give a versatile platform for the development of coming- generation cures with the eventuality to address unmet medical conditions and meliorate patient issues. In this comprehensive review, we will explore the multifaceted terrain of peptidomimetics, probing into their design principles, synthetic methodologies, and remedial operations across various complaint areas. By examining recent advancements and arising trends in peptidomimetic disquisition, we aim to give perceptivity into the transformative eventuality of peptidomimetics in revolutionizing drug discovery and cures. Through a thorough understanding of peptidomimetic design strategies and their operations, we can unleash new openings for the development of innovative cures and pave the way for personalized medicineapproaches adapted to the conditions of individual cases [9].

SIGNIFICANCE OF PEPTIDOMIMETICS

Expanding the Drug gable Space

Peptidomimetics overcome the limitations of natural peptides, expanding the drug gable space by targeting grueling protein-protein relations and intracellular targets preliminarily considered undruggable [10].

Enhanced Pharmacokinetic parcels

Peptidomimetics offer bettered pharmacokinetic parcels similar as enhanced stability, increased bioavailability, and prolonged half- life compared to natural peptides, allowing for further effective delivery and sustained remedial goods [11].

Target particularity and Selectivity

Peptidomimetics can be designed with high target particularity and selectivity, minimizing off- target goods and reducing toxin, thereby perfecting the safety profile of remedial interventions [12].

Structural Diversity and Versatility

Peptidomimetics parade a wide range of structural diversity, from small motes to macrocycles, offering versatility in medicine design and development to target colorful molecular pathways and complaint mechanisms [13].

EASING RATIONAL DRUG DESIGN

Peptidomimetics give a rational approach to medicine design, allowing for the precise manipulation of structural and functional parcels to optimize relations with target proteins and ameliorate remedial efficacy [14].

Prostrating Peptide Limitations

Peptidomimetics address the limitations associated with natural peptides, similar as vulnerability to enzymatic declination and poor membrane permeability, enabling their use asfeasible remedial agents [15].

Modulating Protein Functionality

Peptidomimetics modulate protein functionality by mimicking the list interfaces of natural peptides, dismembering protein-protein relations or enzyme conditioning involved in complaint pathogenesis [16].

Expanding remedial Targets

Peptidomimetics expand the range of drug gable targets by targeting unique list pockets or structural motifs on proteins, enabling the development of curatives for preliminarily unexploredcomplaint pathways [17].

Advancing Precision Medicine

Peptidomimetics play a vital part in advancing perfection drug approaches by allowing for the design

Ofacclimatized curatives that target specific molecular autographs or inheritable mutations associated with individual cases [18].

Combating Drug Resistance

Peptidomimetics offer a strategy to overcome medicine resistance mechanisms by targeting indispensable pathways or developing multitargeted curatives that inhibit multiple complaint- associated proteins contemporaneously [19].

Promoting medicine Delivery

Peptidomimetics serve as protean platforms for medicine delivery, enabling targeted delivery of rectifiers to specific

napkins or cell types, thereby enhancing medicine efficacy and minimizing systemic toxin [20].

Easing Biomolecular Imaging

Peptidomimetics have operations in biomolecular imaging ways, serving as molecular examinations or discrepancy agents for imaging specific biomarkers or complaint- related processes in vivo [21].

SIGNIFICANCE OFEASING RATIONAL DRUG DESIGN

1. Peptidomimetics offer enhanced stability and bioavailability compared to natural peptides, expanding their remedial eventuality.
2. By bridging the gap between peptides and small motes, peptidomimetics give access to new medicine targets and remedial modalities [22].
3. Peptidomimetics overcome the limitations assessed by Lipinski's Rule of 5, thereby expanding the drug gable space and enabling the development of innovative rectifiers [23].
4. The design of peptidomimetics allows for the optimization of pharmacokinetic parcels and target relations, leading to bettered medicine- suchlike characteristics [24].
5. Structural variations in peptidomimetics enable acclimatized parcels for specificremedial operations, enhancing their efficacy and selectivity [25].
6. Peptidomimetics parade a wide range of structural diversity, from small motes to macrocycles, offering versatility in medicine design and development [26].
7. Synthetic strategies for peptidomimetic conflation, similar as solid- phase peptide conflationand result- phase conflation, enable effective assembly of complex structures [27].
8. Peptidomimetics have different operations in targeting protein- protein relations, enzyme inhibition, and beyond, furnishing remedial resultsfor colorful conditions.
9. In cancer remedy, peptidomimetics targeting specific protein- protein relationshold pledge as anticancer agents with bettered efficacy and reduced side goods [28].

APPLICATION:

Cancer Remedy

Targeting Protein- Protein Relations Peptidomimetics Designed To Disrupt Specific Protein- Protein Relations Pivotal For Cancer Cell Survival And Proliferation [29].Enzyme Inhibition Peptidomimetics Act As Impediments Of Enzymes Involved In Cancer Progression, Similar As Kinases And Proteases, By Mimicking Natural Substrates. Anticancer Drug Delivery Peptidomimetics Serve As Carriers For Targeted Medicine Delivery To Cancer Cells, Enhancing Medicine Efficacy And Reducing Systemic Toxin [30].

Infectiousdiseasetherapeutics

Enzyme Inhibition Peptidomimetics Designed To Inhibit Essential Microbial Enzymes, Similar As Proteases And Polymerases, Pivotal For Pathogen Survival And Replication [31].Antiviral Agents Peptidomimetics Developed As Antiviral Agents Targeting Viral Proteins Or Processes Essential For Viral Replication, Similar As Emulsion Impediments And Protease Impediments [32]. Antimicrobial Peptides Peptidomimetics Mimic Natural Antimicrobial Peptides, Dismembering Bacterial Membranes Or Inhibiting Bacterial Cell Wall Conflation, Offering New Treatments For Antibiotic- Resistant Infections [33].

Other Applications:

Peptidomimetics Are Employed In Targeting Protein- Protein Relations, Offering New Remedial Strategies For Conditions Similar As Cancer And Neurodegenerative Diseases. Inhibition Of Enzyme Exertion By Peptidomimetics Has Shown Pledge In The Treatment Of Colorful Conditions, Including Contagious Conditions And Metabolic Disease [34].Peptidomimetics Targeting Specific Protein- Protein Relations Have Surfaced As Implicit Anticancer Agents, Dismembering Crucial Signaling Pathways Involved In Excrescence Growth And Progression. In Contagious Complaint Rectifiers, Peptidomimetics Have Been Developed As Enzyme Impediments Targeting Essential Microbial Enzymes, Offering New Avenues For Antimicrobial Remedy [35]. Peptidomimetics Have Been Explored For Their Eventuality In Modulating Central Nervous System (CNS) Targets, Furnishing Openings For The Treatment Of Neurological Diseases Similar As Alzheimer's Complaint And Parkinson's Complaint. Macrocyclic Peptidomimetics Parade Enhanced Binding Affinity And Selectivity, Making Them Seductive Campaigners For Targeting Protein- Protein Relations And Other Grueling Medicine Targets. Peptidomimetic Enzyme Impediments Have Been Successfully Developed For Colorful Targets, Including Proteases And Kinases, Offering New Remedial Options For Conditions Similar As Cancer And Seditious Diseases [36]. Peptidomimetics Have Shown Pledge In Targeting Specific Metabolic Pathways, Furnishing Implicit Treatments For Metabolic Diseases Similar As Diabetes And Rotundity. The Capability Of Peptidomimetics To Modulate Vulnerable Checkpoints And Protein- Protein Relations Has Led To Their Disquisition In Immunotherapy, Particularly In Cancer Treatment. Peptidomimetics Have Been Delved Fortheir Eventuality In Targeting Angiogenesis And Inflammation, Offering Remedial Approaches For Conditions Characterized By Dysregulated Vascular And Vulnerable Responses [37].

Pharmacological Activies of Peptidomimetic

Anti-ViralActivity

George et al. discovered a number of acyclovir analogues with a thiazide ring including amino acids (glycine, alanine, valine, and leucine) in their search for novel and potent prodrugs to combat the herpes simplex infection. At 37 °C and pH 1 and pH 7.4, the chemical stability of some of the mixtures with various remainders was investigated. Certain esters, namely Gly-thiazole, Ala-thiazide-acyclovir, and Leo-thiazide-acyclovir, shown significant instability, particularly in acidic environments, and underwent rapid fire-fire hydrolysis to yield the chemical precursor acyclovir. The valthiazole-acyclovir peptidomimetic proved remarkably stable at pH 7.4. The acyclovir peptidomimetic Val-thiazide-acyclovir

demonstrated greater stability at this pH than Val acyclovir, the first prodrug of acyclovir that was successful [38].



Figure No: 1 BOC-2-minomethyl-thiazole-acyclovir (BOC-glee-(THz)-ACV)



Figure: 2 BOC-2-ala-thlazole-acyclovir (BOC0ala-(THz)-ACV)



Figure: 3 BOC-2-val-thiazole-acyclovir (BOC-Val-(THz)-ACV)



Figure: 4 BOC-2-leu-thlazole-acyclovir (BOC-lee-(THz)-ACV)

Immune Detection Activity

Mural et al. bared the finding that antibody like binding peptidomimetics (Abe) similar asAnti-Her2/ netpeptidomimetic (AHNP) which is a mimic of Herceptin, a maybe are used for advanced bonecancer remedy [39]. The AHNP has been used as a defining tool to develop immunodetection examinations that illustrate a general process operation [40]. AHNP has been expressed as an oligomeric emulsion protein with streptavidin. These Herceptin like Ibis were used to descry the Her2/ net antigen at extremely low attention using the immunodetection modification fashion (IDAT) [41]. A completely developed largely different library of Ibis represents a volition for panels of monoclonal antibodies and may also be useful for target confirmation, antigen discovery, rectifiers and as a platform for medicine development [42].

Selectivity for DNA Receptors

A peptidomimetic template, conforming of a hydrophobic altar, a damsel fluorophore, and an Argo- His recognition beachfront, was tested by Jeffrey et al. as a simple mimic of zinc cutlet of the Zif268 protein. Association constants (KA's) were on the order of 105 M −1 for complexes formed between the unoriginal and duplexes d (CGGGAATTCCCG) 2 and d (AAAAAAAAATTTTTTTTT) 2. Modest selectivity was observed for the GC-rich DNA in a 0.5 M Nalco/ buffer (0.1 M phosphate, pH 7.0) result [43]. Differences in KA's on with observed CD biographies suggest that the unoriginal associated with the duplexes using different list modes [44]. The DNA duplexes had weaker relations with the free Argo- His recognition beachfront, the damsel functional group, and an altar that contained only glycine's as the recognition beachfront. The altar most probably provides for lesser van der Waal's relations, a larger hydrophobic effect upon association, and reduces the freedom of stir of the side chains [45]. This last effect was

verified by molecular mechanics computations and by the fact that the unoriginal suffered a lower loss of entropic energy upon association than the free recognition beachfront. These studies show that the synthetic altar is a promising platform in which peptides can be attached to increase their affinity and conceivably selectivity for DNA targets [46].

Anti-MalarialActivity

Atari et al. synthesized some new peptidomimetics bearing a defended aspartyl aldehyde warhead leading to the thioacylal and the acyl derivations. Both composites proved to retain an increased antiplasmodial exertion with respect to the parent patch. Likewise, thioacylal be considered as a promising trypanocidal agent [47].

AntioxidantActivity

Mark proposed that l- carnosine- related peptidomimetics N- acetyl carnosine(N- acetyl- h- allay- l- histidine) (NAC) and calcimine(h- alanylhistamine) are metabolically related to l- carnosine and have been demonstrated to do in napkins of numerous invertebrates, including humans, these composites were shown resistant toward enzymatic hydrolysis [48]. A series of affiliated biocompatible imidazole- containing peptidomimetics were synthesized to confer resistance to enzymatic hydrolysis and ex vivo enhancement of defensive ant oxidative parcels related to l-carnosine. The included findings revealed a lesser part of N- acetyl carnosine(NAC) and calcimine ex vivo in the extension and potentiation of physiological responses to the therapeutically and cosmetics treatments with l- carnosine as antioxidant [49]. NAC can act as a time release (carrier) stable interpretation of l- carnosine during operation in ophthalmic medicinal and cosmetics phrasings which include lubricants [50].

Analgesic Activity

Duggan et al. reported the conflation and natural exertion of a low molecular weightnon-peptidic mimic of the analgesic peptide ω- contain GVIA. The molecular weight of this emulsion presents a reduction by 193 µg/ spook compared to a preliminarily reported lead. This emulsion exhibits an EC50 of 5.8 µM and is accessible in only six synthetic way compared to the original lead (13 way). They also report several advancements to the original synthetic route [51].



Figure: 5 O=4 hydroxypyroline 27-residue peptide W-contain GVIA peptide

Design Strategies for Peptidomimetics

Conformational constraints Peptidomimetics incorporate conformational constraints similar as cyclic structures, β-turn mimetics, and peptide pulpits to stabilize bioactive conformations and enhance target affinity. Backbone variations Peptidomimetics employ backbone variations as N- methylation, α- amino acid reserves, and peptide objectification to ameliorate proteolytic stability and enhance oral bioavailability [52]. Side chain variations Peptidomimetics incorporate variations to side chains, similar as relief of natural amino acids with on-canonical amino acids or functional group variations, to optimize relations with target proteins and ameliorate binding affinity.

Scaffold Hopping Peptidomimetics use altar hopping approaches to explore different chemical pulpits and identify newmolecular infrastructureswith betteredpharmacological parcels and target particularity[53]. Computational Design Peptidomimetics employ computational modeling ways, including molecular docking, molecular dynamics simulations, and structure-grounded design, to prognosticate and optimize molecular relations with target proteins, easing rational medicine design and optimization [54].

FUTUREDIRECTIONS:

Difficulties include Perfecting synthetic availability, reducing off- target goods, and optimizing pharmacokinetic features are the focus of unborn enterprise in peptidomimetic exploration [55].Prostrating these obstacles and developing the area will depend critically on creative medicine delivery styles, enhanced computer modeling approaches, and new design tactics [56]. Likewise, there's

an adding interest in probing the possibilities of peptidomimetics in slice- edge fields including immunotherapy, regenerative drug, and perfection drug, which is creating new openings for innovative rectifiers. Unborn developments in peptidomimetic exploration and its restatement into remedial operations will be largely dependent on the integration of interdisciplinary methodologies, similar as computational chemistry, structural biology, and synthetic chemistry [57]. To completely realize the remedial eventuality of peptidomimetics and satisfy the changing demands of cases in the future, it'll be imperative to break these limitations and embrace new exploration approaches [58].

CONCLUSION:

Peptidomimetics, in comparison to natural peptides, offer improvedstability, selectivity, and adaptability, hence representing a paradigm shift in drug development and therapy. Peptidomimetics, which bridge the gap between peptides and small molecules, have increasedthe drug gable space and made it possible to create new therapeuticapproaches. Peptidomimetics show potential in customized medicine approachesand addressing individual therapeutic demands across many disease are as when combined with logical design methodologies and structural alterations. To effectively utilize peptidomimetics in clinical applications, however, obstacles including pharmacokinetic property optimization and off-target effect minimization must be addressed in future study.

Peptidomimetics has the potential to transform drug development and influence precision medicine in the future by adopting inters disciplinary techniques and investigating novel research a venues.

REFERENCES:

1. R.C. Milton; S.C. Milton; S.B. Kent. Science, 1992; 256:1445-1448.
2. Trabocchi, Andrea. "Principles and applications of small molecule peptidomimetics." *Small molecule drug discovery*. Elsevier, (2020). 163-195.
3. Farmer, P. S.; Ariëns, E. J. Speculations on the design of nonpeptidic peptidomimetics Trends Pharmacol. Sci. 1982; 3, 362– 365
4. Giannis, A.; Kolter, T. Peptidomimetics for receptor ligands -- discovery, developoment, and medical perspectives Angew. Chem., Int. Ed. 1993; 32:1244– 1267
5. Wiley, R. A.; Rich, D. H. Peptidomimetics derived from natural products Med. Res. Rev. (1993), 13: 327– 384
6. Gante, J. Peptidomimetics—tailored enzyme inhibitors Angew. Chem., Int. Ed. 1994;33:1699– 1720
7. D.J. Abraham. Burger's Medicinal Chemistry and Drug Discovery, 6th edition, John Wiley and Sons, New Jersey, 2003; 1: 634-636.
8. Smith, J. etal. Strategies for the Design of Peptidomimetics. Chemical Reviews. (2019). 120(8), 3781-3810.
9. Patel, S.etal Therapeutic Applications of Peptidomimetics: Targeting Protein-Protein Interactions, Enzyme Inhibition, and Beyond. Nature Reviews Drug Discovery,2016; 16(12):826-843.
10. Doak, B. C. et al. Expanding the Druggable Space withPeptidomimetics: Beyond the Rule of 5. Chemistry & Biology, 2019; 22(9):1115-1142.
11. Smith, J.etal. Strategies for the Design of Peptidomimetics. Chemical Reviews, 2019; 120(8):3781-3810.
12. Patel, S.etal. Therapeutic Applications of Peptidomimetics: Targeting Protein-Protein Interactions, Enzyme Inhibition, and Beyond. Nature Reviews Drug Discovery, 2016; 16(12):826-843.
13. Brown, A. et al. Structural Diversity of Peptidomimetics: From Small Moleculesto Macrocycles. Accounts of Chemical Research, 2018; 52(10): 2804-2815.
14. Lee, K.etal.Challenges and Opportunities in Peptidomimetic Research. Trends in Pharmacological Sciences, 2015; 37(9):720-731.
15. Gupta, N. et al. Peptidomimetics: A Synthetic Tool forInhibiting Protein-Protein Interactions in Cancer. International Journal of Peptide Research and Therapeutics, 2017; 23(4):493-504.
16. Schafmeister, C.E.etal. Peptidomimetics in Drug Design: Discovering Peptide Mimeticsto Leadthe Way. Current Opinionin Chemical Biology,2000;4(4):445-451.
17. Lau, J. L. et al. Peptide and Peptidomimetic ModulatorsofProtein-ProteinInteraction:AMolecularApproach.JournalofMedicinal Chemistry,(2019). 63(1),8-32.
18. Sakai, N. et al. Peptidomimetics as a New Generation of Antimicrobial Agents: Current Progress. Molecules 2013;18(1):4280-4294.
19. Chen, L. et al. Peptidomimetics as Potential Therapeutics for Malaria. Frontiers in Chemistry 2018; 6:146.
20. Wu, X .etal. Peptidomimetics as Antiviral Agents: Recent Advances and Challenges. Drug Discovery Today 2019; 24(10):2011-2019.
21. Krchňák,V.etal. Peptidomimetics and Their Applications in Biomedical Research.Current Opinionin Biotechnology, 2002; 13(4):315-319.
22. Jimmidi, Ravikumar, et al. "DNA-encoded chemical libraries yield non-covalent and non-peptidic SARS-CoV-2 main protease inhibitors." *Communications Chemistry* 6.1 (2023): 164.
23. Cicaloni, Vittoria, et al. "Applications of in silico methods for design and development of drugs targeting protein-protein interactions." *Current topics in medicinal chemistry* 19.7 (2019): 534-554.
24. Kelso, Michael J., and David P. Fairlie. "Current approaches to peptidomimetics." *Molecular Pathomechanisms and New Trends in Drug Research*. CRC Press, 2002. 597-616.
25. Cescon, M., et al. "Valorization of seafood processing waste as bio-adsorbent material for water remediation." *Atti del XXIX Congresso della Divisione di Chimica Analitica della Società Chimica Italiana*. Società Chimica Italiana, 2022.
26. Isidro-Llobet, Albert, et al. "Diversity-oriented synthesis of macrocyclic peptidomimetics." *Proceedings of the National Academy of Sciences* 108.17 (2011): 6793-6798.
27. Yang, Kai-Chieh, et al. "Crystallization-Induced Flower-like Superstructures via Peptoid Helix Assembly." *ACS Macro Letters* 13.4 (2024): 423-428.
28. Panzeri, Silvia. "Synthesis and biomedical applications of novel RGD and iso DGR integrin ligands." (2016).
29. Wang, Junyuan, et al. "Rational design of small-sized peptidomimetic inhibitors disrupting protein–protein interaction." *RSC Medicinal Chemistry* (2024).
30. Gomari, Mohammad Mahmoudi, et al. "Peptidomimetics in cancer targeting." *Molecular Medicine* 28.1 (2022): 146.
31. Martínez, Osmel Fleitas, Harry Morales Duque, and Octávio Luiz Franco. "Peptidomimetics as potential anti-virulence drugs against resistant bacterial pathogens." *Frontiers in Microbiology* 13 (2022): 831037.
32. Borges, Pedro Henrique Oliveira, Sabrina Baptista Ferreira, and Floriano Paes Silva Jr. "Recent Advances on Targeting Proteases for Antiviral Development." *Viruses* 16.3 (2024): 366.
33. Weeks, Richard, Ammar Algburi, and Michael Chikindas. "Antimicrobial peptides and peptidomimetics for the control of antimicrobial resistance." *SustainableAgriculture Reviews 49: Mitigation of Antimicrobial Resistance Vol 2. Natural and Synthetic Approaches* (2021): 205-249.
34. Zhang, Gan, Jessica Andersen, and Guillermo Gerona-Navarro. "Peptidomimetics targeting protein-protein interactions for therapeutic development." *Protein and peptide letters* 25.12 (2018): 1076-1089.

35. Dar, Khalid B., et al. "Exploring proteomic drug targets, therapeutic strategies and protein-protein interactions in cancer: mechanistic view." *Current cancer drug targets* 19.6 (2019): 430-448.

36. Matias, Mariana, et al. "Recent highlights on molecular hybrids potentially useful in central nervous system disorders." *Mini Reviews in Medicinal Chemistry* 17.6 (2017): 486-517.

37. Litmanovich, Adi, et al. "Noncardiovascular-derived therapeutic peptidomimetics in cardiovascular disease." *Peptide and Peptidomimetic Therapeutics*. Academic Press, 2022. 615-654.

38. Hristov, Georgi, and Ivanka Stankova. "Chemical stability of new acyclovir analogues with peptidomimetics." *Scientia Pharmaceutica* 79.2 (2011): 259-264.

39. Pathak, Manish Kumar, et al. "Review on peptidomimetics: a drug designing tool." *American Journal of Pharmaceutical Research* 5.12 (2015).

40. Murali, R., et al. "Antibody like peptidomimetics as large scale immunodetection probes." *Cellular and Molecular Biology (Noisy-le-Grand, France)* 49.2 (2003): 209-216.

41. Mabonga, Lloyd, Priscilla Masamba, and Abidemi Paul Kappo. "Therapeutic peptidomimetics: targeting the undruggable space." *Peptide and Peptidomimetic Therapeutics*. Academic Press, 2022. 37-55.

42. Kuester, Katharina, and Charlotte Kloft. "Pharmacokinetics of monoclonal antibodies." *Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development* (2006): 45-91.

43. Sidde, Lahari, C. Akhil, and C. Manikanta. "Assessment of numerous novel peptidomimetics." *Journal of Integral Sciences* (2022): 1-8.

44. Zhao, Andong, et al. "Chiral metallohelices enantioselectively target hybrid human telomeric G-quadruplex DNA." *Nucleic acids research* 45.9 (2017): 5026-5035.

45. Vij, Varun, Vandana Bhalla, and Manoj Kumar. "Hexaarylbenzene: evolution of properties and applications of multitalented scaffold." *Chemical Reviews* 116.16 (2016): 9565-9627.

46. Banavali, Nilesh K., and Alexander D. MacKerell Jr. "Free energy and structural pathways of base flipping in a DNA GCGC containing sequence." *Journal of molecular biology* 319.1 (2002): 141-160.

47. Ettari, Roberta, et al. "Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis." *Journal of Medicinal Chemistry* 56.14 (2013): 5637-5658.

48. Kharb, Rajeev, et al. "Therapeutic importance of peptidomimetics in medicinal chemistry." *J. Chem. Pharm. Res* 3.6 (2011): 173-186.

49. Babizhayev, Mark A. "Biological activities of the natural imidazole-containing peptidomimetics n-acetylcarnosine, carcinine and L-carnosine in ophthalmic and skin care products." *Life sciences* 78.20 (2006): 2343-2357.

50. Babizhayev, Mark A., Inna P. Khoroshilova-Maslova, and Anne Kasus-Jacobi. "Novel intraocular and systemic absorption drug delivery and efficacy of N-acetylcarnosine lubricant eye drops or carcinine biologics in pharmaceutical usage and therapeutic vision care." *Fundamental & clinical pharmacology* 26.5 (2012): 644-678.

51. Duggan, Peter J., and Kellie L. Tuck. "Bioactive mimetics of conotoxins and other venom peptides." *Toxins* 7.10 (2015): 4175-4198.

52. Lenci, Elena, and Andrea Trabocchi. "Peptidomimetic toolbox for drug discovery." *Chemical Society Reviews* 49.11 (2020): 3262-3277.

53. Castro, Tarsila G., et al. "Non-Canonical Amino Acids as Building Blocks for Peptidomimetics: Structure, Function, and Applications." *Biomolecules* 13.6 (2023): 981.

54. Adelusi, Temitope Isaac, et al. "Molecular modeling in drug discovery." *Informatics in Medicine Unlocked* 29 (2022): 100880.

55. Yang, Wenzhan, et al. "The evolving druggability and developability space: chemically modified new modalities and emerging small molecules." *The AAPS journal* 22 (2020): 1-14.

56. Hassan Baig, Mohammad, et al. "Computer aided drug design: success and limitations." *Current pharmaceutical design* 22.5 (2016): 572-581.

57. Synoradzki, Kamil J., et al. "From molecular biology to novel immunotherapies and nanomedicine in uveal melanoma." *Current Oncology* 31.2 (2024): 778-800.

58. Wang, Jiajun, et al. "Antimicrobial peptides: Promising alternatives in the post feeding antibiotic era." *Medicinal research reviews* 39.3 (2019): 831-859.